You are here: Industry Insights > gilead

News List

Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval firstwordpharma
December 24, 2019
Approximately 600,000 to 1 million people are living with RA across Japan, and despite available options, many still do not experience disease remission.
Gilead Submits Filgotinib NDA for Rheumatoid Arthritis Treatment americanpharmaceuticalreview
December 24, 2019
Gilead Sciences has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the ...
Gilead, Galapagos close their development collaboration biospectrumasia
August 26, 2019
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
Enough hubbub about HHS' Truvada patents, Gilead says. We're challenging them at the PTO fiercepharma
August 25, 2019
Drugmakers have often lambasted the U.S. Patent and Trademark Office’s (PTO's) inter partes review system, but now Gilead Sciences is hoping to use it to its advantage.
China approves Gilead’s HIV-1 drug candidate Biktarvy pharmaceutical-technology
August 13, 2019
The China National Medical Products Administration (NMPA) has approved Gilead Sciences’ Biktarvy, a once-daily single-tablet regimen (STR) to treat HIV-1 infection.
Agenus, Gilead Milestone Triggers $7.5M Payment contractpharma
August 09, 2019
FDA acceptance of IND filing for AGEN237 represents the second milestone in Gilead partnership achieved in 2019.
Gilead's Descovy seems set for a PrEP nod in men, FDA review shows. But what about women? fiercepharma
August 07, 2019
As FDA panel experts gear up to debate the merits of Gilead’s Descovy for HIV prevention, the question doesn’t seem to be whether it’s worthy of an indication in men, the largest part of the market. It’s whether it should get a green light in women.
Gilead's exec search won't hurt its deal search fiercepharma
August 01, 2019
New Gilead CEO Daniel O’Day has some major holes to fill when it comes to executive hiring. But he insists the C-suite search won’t slow the company’s search for M&A targets.
Gilead gets licences to three antiviral programmes from Novartis pharmaceutical-technology
July 23, 2019
Gilead Sciences has secured an antiviral deal with Novartis to gain exclusive global rights to preclinical programmes involving candidates for the treatment of various viral infections.
Gilead and Galapagos deepen R&D alliance with ten-year deal pharmaceutical-technology
July 17, 2019
Gilead Sciences has expanded its partnership with Belgian biotech company Galapagos with a ten-year global research and development (R&D) deal.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page